For the first time in its operational history, PharmaCielo Ltd (OTCMKTS: PCLOF) is spreading its wings to take on THC products and has entered into a joint venture with Greenstein Germany GmbH. As a result, PharmaCielo will supply NOWEDA, a German pharmacist-owned cooperative, with three THC-dominant final products. The new opportunity knocks at a time when PharmaCielo is very expectant of a pivotal year in 2022 both in Europe as well as in other focus markets globally.
The Collaboration Represents a Massive Early Success for Both Companies
Hundreds of businesses embracing partnerships and joint ventures, having lost so much of their strongholds to the pandemic. The primary purpose is to get back on their business while strengthening their sales channels. Both PharmaCielo and NOWEDA are cut for the same outfit because they have a substantial opportunity into a long–term benefit.
Greenstein has access to one of Germany’s leading pharmaceutical wholesale distribution networks. On the other hand, PharmaCielo has world-leading cultivating and processing facilities. Hence, it is uniquely positioned to supply the German market. There is already looming success for both companies, and this is just the beginning of opportunities.
Co-Founder and CEO of Greenstein, Matthias Koeppel, outlined, “… We are excited to bring to market their excellent product portfolio through our network…We see this as a first, but confident and strong step in securing high quality, competitively priced THC products for the German market.”
PharmaCielo’s Update on Latin American Sales Progress
The pharmaceutical sales cycle is long-tail by nature. New products come and go, but manufacturers and suppliers involved in the product development end up being winners aftermarket development. PharmaCielo has all the necessary capabilities to maintain a pole position in the developing industry.
The company is actively working with other institutions across the globe to maximize its operations. For example, it is in the negotiation stage of a multi-year sales agreement with a pharmaceutical company in Argentina with over 80 years of history. PhamaCielo is also pursuing an established Phytotherapeutic company in the Brazilian market and another in Paraguay. All these are promising, and PhamaCielo is set to leap big given that it is focusing on supplying the international marketplace.
